Nifty 50
Tools & Calculators
Stocks
F&O
Mutual Funds
HDFC Pharma and Healthcare Reg IDCW-R
as of 22 Jul 2026, 18:53 PM
Invested Amount
Est. Return
Total Value
rated by Value Research
Your principal will be at Very High Risk
Absolute Returns
CAGR
Equity / Debt / Cash Split
Equity
98.7%
Cash
1.3%
Equity sector allocation
Basic Materials
4.5%
Healthcare
94.2%
Others
1.3%
Asset Management Company

Nippon India Taiwan Equity Reg Gr
Equity
Min. Investment
₹500
Category Returns
29.75%
63.78%
3Y Returns
+63.78%

DSP Wld Gld Mng Ovrs Eq Omni FoF Gr
Equity
Min. Investment
₹100
Category Returns
29.75%
63.78%
3Y Returns
+45.98%

DSP Wld Gld Mng Ovrs Eq Omni FoF IDCW-R
Equity
Min. Investment
₹100
Category Returns
29.75%
63.78%
3Y Returns
+45.89%
Investment Objective of the Scheme
Key Features of The Fund
5-year return
-
Fund Manager
Dhruv Muchhal
Risk Profile
Very High Risk
Expense Ratio
1.97%
Fund Size
₹2362.44 Cr
HDFC Pharma and Healthcare Reg IDCW-R is currently priced at ₹19.76, as of 22 Jul 2026, 18:53 PM. The fund has recorded a change of ₹0.21 (1.06%), indicating its recent movement in the market.
Tracking NAV trends helps investors understand short-term price movement, while long-term performance gives a better picture of wealth creation potential.
HDFC Pharma and Healthcare Reg IDCW-R is an open-ended mutual fund that invests based on its stated objective and benchmark.
Key details:
Asset Size: ₹2362.44 Cr
Expense Ratio: 1.97%
Cash Holding: 1.30%
Plan Type: Dividend
Benchmark: BSE Healthcare TR INR
Launch Date: 2023-10-04
Exit Load: 1.00
These factors help investors evaluate cost, scale, and fund positioning before making an investment decision.
HDFC Pharma and Healthcare Reg IDCW-R has delivered returns across multiple timeframes, reflecting its ability to perform across different market conditions.
Returns:
1 Month: 2.54%
3 Months: 14.92%
6 Months: 16.16%
1 Year: 20.26%
3 Years: -
5 Years: -
Short-term returns indicate recent momentum, while long-term returns show consistency and wealth creation ability.
Understanding risk is important before investing. HDFC Pharma and Healthcare Reg IDCW-R falls under: For investors in the 20–40 age group, selecting a fund with the right risk level is important based on financial goals, investment horizon, and comfort with market movements.
Risk Level: Very High Risk
The riskometer helps investors understand how stable or volatile the fund can be based on its investment strategy and asset allocation. Funds with higher risk levels may offer better return potential over time, but they can also experience sharper short-term fluctuations. This classification reflects the volatility associated with the fund. Higher risk funds may offer higher returns but come with greater fluctuations.
The asset allocation of HDFC Pharma and Healthcare Reg IDCW-R shows how investments are distributed across asset classes.
Equity Allocation: 98.70%
Cash Allocation: 1.30%
This allocation plays a key role in determining the fund’s risk and return profile.
HDFC Pharma and Healthcare Reg IDCW-R diversifies its investments across sectors to reduce risk.
Sector Holding Detail
Basic Materials: 4.50%
Healthcare: 94.20%
Sector allocation data helps investors understand which industries the fund is focusing on.
HDFC Pharma and Healthcare Reg IDCW-R is managed by:
AMC Name: HDFC Asset Management Co Ltd
A strong fund house with a proven track record can improve investor confidence.
Investors can start investing in HDFC Pharma and Healthcare Reg IDCW-R with:
Minimum Investment: ₹100
This makes the fund accessible for both beginners and experienced investors.
The HDFC Pharma and Healthcare Reg IDCW-R has invested the majority of its money in the stocks of the following companies:
| Company | Percentage of Portfolio |
|---|---|
| Sun Pharmaceuticals Industries Ltd | 9.20% |
| Divi's Laboratories Ltd | 8.02% |
| Lupin Ltd | 5.45% |
| Max Healthcare Institute Ltd Ordinary Shares | 5.26% |
| Aster DM Healthcare Ltd Ordinary Shares | 5.18% |
| Cipla Ltd | 4.92% |
| Acutaas Chemicals Ltd | 4.50% |
| Alkem Laboratories Ltd | 4.36% |
| Anthem Biosciences Ltd | 4.15% |
| Ipca Laboratories Ltd | 3.50% |
| Fortis Healthcare Ltd | 3.41% |
| Glenmark Pharmaceuticals Ltd | 3.28% |
| Laurus Labs Ltd | 3.17% |
| Krishna Institute of Medical Sciences Ltd | 3.16% |
| Global Health Ltd | 3.08% |
| Neuland Laboratories Ltd | 2.98% |
| Vijaya Diagnostic Centre Ltd | 2.70% |
| Metropolis Healthcare Ltd | 2.54% |
| Zydus Lifesciences Ltd | 2.50% |
| Wockhardt Ltd | 2.44% |
| Shilpa Medicare Ltd | 2.28% |
| Sai Life Sciences Ltd | 1.78% |
| Eris Lifesciences Ltd Registered Shs | 1.61% |
| Thyrocare Technologies Ltd | 1.54% |
| Rubicon Research Ltd | 1.35% |
| Jubilant Pharmova Ltd | 1.34% |
| Biocon Ltd | 1.33% |
| Gland Pharma Ltd | 1.19% |
| Bajaj Healthcare Ltd | 0.73% |
| Novartis India Ltd | 0.64% |
| Laxmi Dental Ltd | 0.63% |
| Cohance Lifesciences Ltd | 0.46% |
| Treps - Tri-Party Repo | 1.49% |
| Net Current Assets | 0.18% |
| Torrent Pharmaceuticals Ltd | - |
The HDFC Pharma and Healthcare Reg IDCW-R has invested the majority of its money in the stocks of the following sectors -
| Company | Percentage of Portfolio |
|---|---|
| Basic Materials | 4.50% |
| Healthcare | 94.20% |
Investing in mutual funds is easy on HDFC SKY.
Follow these simple steps to invest in HDFC Pharma and Healthcare Reg IDCW-R:
By signing up I certify terms, conditions & privacy policy